A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants

NCT01933880 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

194

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Hyperactivity Disorder (ADHD)

Interventions

DRUG: Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH)
OTHER: No intervention

Sponsor

Xian-Janssen Pharmaceutical Ltd.